126 related articles for article (PubMed ID: 37917111)
1. A Pilot Nonrandomized Controlled Trial Examining the Use of Artificial Tears on the Radioactivity of Tears After Radioactive Iodine Treatment for Thyroid Cancer.
Lee IT; Grice JV; Ji X; Chen Q; Bischoff LA; Jessop AC; Barahimi B; Codere F; Mawn LA; Sobel RK
Thyroid; 2024 Jan; 34(1):82-87. PubMed ID: 37917111
[No Abstract] [Full Text] [Related]
2. Factors Associated With Radioactive Iodine Therapy-Acquired Nasolacrimal Duct Obstruction.
Lee IT; Chen W; Chen Q; Cole HA; Bischoff LA; Jessop AC; Sobel RK
Endocr Pract; 2022 Dec; 28(12):1210-1215. PubMed ID: 35970353
[TBL] [Abstract][Full Text] [Related]
3. Surgical Risk Prediction for Nasolacrimal Duct Obstruction in Radioactive Iodine-Treated Thyroid Cancer: A Nationwide Cohort Study.
Lee JY; Woo KI
Thyroid; 2022 May; 32(5):544-551. PubMed ID: 34894720
[No Abstract] [Full Text] [Related]
4. Endoscopic dacryocystorhinostomy following radioactive iodine thyroid ablation.
Van Tassel SH; Segal KL; Hsu NM; Kacker A; Lelli GJ
Orbit; 2017 Apr; 36(2):59-63. PubMed ID: 28388347
[TBL] [Abstract][Full Text] [Related]
5. [Lacrimal drainage system obstruction associated to radioactive iodine therapy for thyroid carcinoma].
Fonseca FL; Lunardelli P; Matayoshi S
Arq Bras Oftalmol; 2012; 75(2):97-100. PubMed ID: 22760799
[TBL] [Abstract][Full Text] [Related]
6. Probing for congenital nasolacrimal duct obstruction.
Petris C; Liu D
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD011109. PubMed ID: 28700811
[TBL] [Abstract][Full Text] [Related]
7. Visualization of nasolacrimal drainage system after radioiodine therapy in patients with thyroid cancer.
Sakahara H; Yamashita S; Suzuki K; Imai M; Kosugi T
Ann Nucl Med; 2007 Nov; 21(9):525-7. PubMed ID: 18030585
[TBL] [Abstract][Full Text] [Related]
8. Dacryoendoscopic Findings of Patients with Lacrimal Drainage Obstruction Associated with Cancer Treatment.
Kim Y; Lew H
Korean J Ophthalmol; 2022 Dec; 36(6):509-517. PubMed ID: 36220641
[TBL] [Abstract][Full Text] [Related]
9. Topical pharmacologic interventions versus placebo for epidemic keratoconjunctivitis.
Liu SH; Hawkins BS; Ng SM; Ren M; Leslie L; Han G; Kuo IC
Cochrane Database Syst Rev; 2022 Mar; 3(3):CD013520. PubMed ID: 35238405
[TBL] [Abstract][Full Text] [Related]
10. Nasolacrimal duct obstruction associated with radioactive iodine therapy for thyroid carcinoma.
Shepler TR; Sherman SI; Faustina MM; Busaidy NL; Ahmadi MA; Esmaeli B
Ophthalmic Plast Reconstr Surg; 2003 Nov; 19(6):479-81. PubMed ID: 14625496
[TBL] [Abstract][Full Text] [Related]
11. Prophylactic prednisolone for the prevention of early and intermediate adverse effects of radioactive iodine therapy in patients with thyroid cancer: study protocol for a single-centre, phase II/III, randomized, double-blinded, placebo-controlled clinical trial.
Jayarajah U; Wijekoon M; Seneviratne SA
Trials; 2020 Sep; 21(1):812. PubMed ID: 32993815
[TBL] [Abstract][Full Text] [Related]
12. Nasolacrimal duct obstruction as a complication of iodine-131 therapy in patients with thyroid cancer.
Fard-Esfahani A; Farzanefar S; Fallahi B; Beiki D; Saghari M; Emami-Ardekani A; Majdi M; Eftekhari M
Nucl Med Commun; 2012 Oct; 33(10):1077-80. PubMed ID: 22825036
[TBL] [Abstract][Full Text] [Related]
13. Tear protein analysis in patients with primary acquired nasolacrimal duct obstruction treated with lacrimal passage intubation.
Yaginuma S; Konno K; Shigeyasu C; Yamada M
Jpn J Ophthalmol; 2021 May; 65(3):409-415. PubMed ID: 33411097
[TBL] [Abstract][Full Text] [Related]
14. The Effect of Radioactive Iodine Therapy on Ovarian Function and Fertility in Female Thyroid Cancer Patients: A Systematic Review and Meta-Analysis.
Piek MW; Postma EL; van Leeuwaarde R; de Boer JP; Bos AME; Lok C; Stokkel M; Filipe MD; van der Ploeg IMC
Thyroid; 2021 Apr; 31(4):658-668. PubMed ID: 33012254
[No Abstract] [Full Text] [Related]
15. Epiphora after radioactive iodine ablation for thyroid cancer.
Sun GE; Hatipoglu B
Thyroid; 2013 Feb; 23(2):243-5. PubMed ID: 22946448
[TBL] [Abstract][Full Text] [Related]
16. Salivary gland dysfunction and nasolacrimal duct obstruction: stenotic changes following I-131 therapy.
Savage MW; Sobel RK; Hoffman HT; Carter KD; Finkelstein MW; Shriver EM
Ophthalmic Plast Reconstr Surg; 2015; 31(3):e50-2. PubMed ID: 24836449
[TBL] [Abstract][Full Text] [Related]
17. Expression of sodium iodide symporter in the lacrimal drainage system: implication for the mechanism underlying nasolacrimal duct obstruction in I(131)-treated patients.
Morgenstern KE; Vadysirisack DD; Zhang Z; Cahill KV; Foster JA; Burns JA; Kloos RT; Jhiang SM
Ophthalmic Plast Reconstr Surg; 2005 Sep; 21(5):337-44. PubMed ID: 16234694
[TBL] [Abstract][Full Text] [Related]
18. Dependence of radioactive iodine-131 capture by the lacrimal ducts on the tear production level.
Yartsev VD; Sheremeta MS; Trukhin AA; Atkova EL; Degtyarev MV; Yasyuchenya VS; Yudakov DV
Indian J Ophthalmol; 2023 May; 71(5):1828-1832. PubMed ID: 37203037
[TBL] [Abstract][Full Text] [Related]
19. The effect of selenium supplementation on sonographic findings of salivary glands in papillary thyroid cancer (PTC) patients treated with radioactive iodine: study protocol for a double-blind, randomized, placebo-controlled clinical trial.
Amini S; Golshani M; Moslehi M; Hajiahmadi S; Askari G; Iraj B; Bagherniya M
Trials; 2023 Aug; 24(1):501. PubMed ID: 37550760
[TBL] [Abstract][Full Text] [Related]
20. Radioiodine-Induced Salivary Gland Damage Detected by Ultrasonography in Patients Treated for Papillary Thyroid Cancer: Radioactive Iodine Activity and Risk.
Horvath E; Skoknic V; Majlis S; Tala H; Silva C; Castillo E; Whittle C; Niedmann JP; González P
Thyroid; 2020 Nov; 30(11):1646-1655. PubMed ID: 32370663
[No Abstract] [Full Text] [Related]
[Next] [New Search]
